Kobayashi Pharmaceutical Co., Ltd. (TYO:4967)
5,631.00
-32.00 (-0.57%)
Mar 13, 2025, 3:30 PM JST
Kobayashi Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Cash & Equivalents | 50,873 | 71,536 | 96,233 | 95,024 | 78,253 | Upgrade
|
Short-Term Investments | 14,872 | 8,300 | 8,300 | 14,022 | 16,085 | Upgrade
|
Cash & Short-Term Investments | 65,745 | 79,836 | 104,533 | 109,046 | 94,338 | Upgrade
|
Cash Growth | -17.65% | -23.63% | -4.14% | 15.59% | 4.18% | Upgrade
|
Receivables | 49,384 | 52,984 | 47,853 | 55,147 | 52,829 | Upgrade
|
Inventory | 24,163 | 22,081 | 17,678 | 15,107 | 14,139 | Upgrade
|
Other Current Assets | 5,176 | 3,430 | 2,828 | 2,589 | 2,919 | Upgrade
|
Total Current Assets | 144,468 | 158,331 | 172,892 | 181,889 | 164,225 | Upgrade
|
Property, Plant & Equipment | 67,448 | 47,665 | 34,778 | 22,524 | 20,821 | Upgrade
|
Long-Term Investments | 28,421 | 36,083 | 32,123 | 33,177 | 38,382 | Upgrade
|
Goodwill | 9,260 | 9,655 | 7,147 | 7,189 | 7,284 | Upgrade
|
Other Intangible Assets | 11,414 | 11,959 | 6,160 | 5,469 | 5,510 | Upgrade
|
Long-Term Deferred Tax Assets | 3,087 | 2,647 | 1,750 | 1,489 | 1,443 | Upgrade
|
Other Long-Term Assets | 1 | 1 | 2 | 1 | 1 | Upgrade
|
Total Assets | 265,368 | 267,473 | 255,827 | 252,554 | 238,366 | Upgrade
|
Accounts Payable | 14,688 | 17,305 | 18,056 | 17,444 | 15,926 | Upgrade
|
Accrued Expenses | 2,840 | 2,705 | 2,553 | 2,486 | 2,797 | Upgrade
|
Short-Term Debt | - | - | - | 1 | 13 | Upgrade
|
Current Portion of Leases | 343 | 379 | 261 | 169 | 170 | Upgrade
|
Current Income Taxes Payable | 19,376 | 29,884 | 25,317 | 25,662 | 26,756 | Upgrade
|
Other Current Liabilities | 9,176 | 5,838 | 5,622 | 4,941 | 4,445 | Upgrade
|
Total Current Liabilities | 46,423 | 56,111 | 51,809 | 50,703 | 50,107 | Upgrade
|
Long-Term Leases | 503 | 608 | 531 | 460 | 505 | Upgrade
|
Long-Term Deferred Tax Liabilities | 1,554 | 2,594 | 1,310 | 1,564 | 1,357 | Upgrade
|
Other Long-Term Liabilities | 2,413 | 2,405 | 2,244 | 2,209 | 1,855 | Upgrade
|
Total Liabilities | 51,898 | 62,657 | 57,928 | 56,955 | 55,784 | Upgrade
|
Common Stock | 3,450 | 3,450 | 3,450 | 3,450 | 3,450 | Upgrade
|
Additional Paid-In Capital | 522 | 522 | 522 | 4,183 | 4,183 | Upgrade
|
Retained Earnings | 208,240 | 205,681 | 194,285 | 200,534 | 187,071 | Upgrade
|
Treasury Stock | -24,767 | -24,766 | -14,482 | -23,706 | -19,763 | Upgrade
|
Comprehensive Income & Other | 26,021 | 19,929 | 14,124 | 11,138 | 7,641 | Upgrade
|
Total Common Equity | 213,466 | 204,816 | 197,899 | 195,599 | 182,582 | Upgrade
|
Minority Interest | 4 | - | - | - | - | Upgrade
|
Shareholders' Equity | 213,470 | 204,816 | 197,899 | 195,599 | 182,582 | Upgrade
|
Total Liabilities & Equity | 265,368 | 267,473 | 255,827 | 252,554 | 238,366 | Upgrade
|
Total Debt | 846 | 987 | 792 | 630 | 688 | Upgrade
|
Net Cash (Debt) | 64,899 | 78,849 | 103,741 | 108,416 | 93,650 | Upgrade
|
Net Cash Growth | -17.69% | -23.99% | -4.31% | 15.77% | 4.44% | Upgrade
|
Net Cash Per Share | 873.02 | 1039.65 | 1344.98 | 1387.72 | 1198.14 | Upgrade
|
Filing Date Shares Outstanding | 74.34 | 74.34 | 76.13 | 77.28 | 78.16 | Upgrade
|
Total Common Shares Outstanding | 74.34 | 74.34 | 76.01 | 77.74 | 78.16 | Upgrade
|
Working Capital | 98,045 | 102,220 | 121,083 | 131,186 | 114,118 | Upgrade
|
Book Value Per Share | 2871.53 | 2755.17 | 2603.46 | 2516.20 | 2335.91 | Upgrade
|
Tangible Book Value | 192,792 | 183,202 | 184,592 | 182,941 | 169,788 | Upgrade
|
Tangible Book Value Per Share | 2593.42 | 2464.42 | 2428.40 | 2353.37 | 2172.23 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.